Continuous Antibiotic Infusion In Children
Key facts
- Who runs it
- Tampere University Hospital
- Where
- Finland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 150 people, planned
- Started
- 21 Apr 2026
- Expected to end
- 31 Dec 2031
- Type of study
- Interventional
- Treatments tested
- Benzylpenicillin
- Record updated
- 8 May 2026
Who can take part
- Age
- Up to 16 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- iv-antibiotic treatment is necessary
- clinically stable
- no need to stay in hospital
- pump or cassette can be changed at the hospital or at home
- care givers are able to contact hospital if needed
- clinical diagnose is not uncertain
- no allergy for the used antibiotic
- the continuous antibiotic infusion hasn't been started yet or it has been initiated no more than 24 hours prior to study enrolment
Who cannot take part
- the pump cannot be carried with the child
- the child must stay at the hospital for monitoring or other reason
- unclear diagnose
This trial is currently available in Finland.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Continuous intravenous antibiotic infusion using elastomeric pumps is well established in adult care and has been shown to be effective, safe, and cost-efficient, particularly for beta-lactams and vancomycin. In pediatric outpatient parenteral antimicrobial therapy (p-OPAT), home intravenous treatment is feasible and safe, improves quality of life, and reduces hospital stays and healthcare-associated infections. Elastomeric pumps offer practical advantages, including portability, ease of use, fixed infusion rates, and reduced drug handling, although they are limited by fixed flow rates and drug stability.
Read full original descriptionShow less
This prospective study at Tampere University Hospital (Tays) will evaluate the safety and cost-effectiveness of 24-hour continuous antibiotic infusions in children between January 2026 and January 2029. Eligible pediatric patients requiring intravenous antimicrobial treatment and suitable for home care will be included. Indications include serious bacterial infections such as bacteremia, osteomyelitis, septic arthritis, neutropenic fever, cystic fibrosis-related infections, and foreign body infections. The study antibiotics are benzylpenicillin, cloxacillin, piperacillin/tazobactam, and vancomycin, administered via CE-approved infusion devices for home use.
Children will receive continuous infusion either initially in hospital or directly from the emergency department if appropriate, with treatment duration and dosing comparable to standard intermittent regimens. Outcomes include safety, feasibility, cost-effectiveness, and patient-reported quality of life measured using PedsQL™. The study aims to determine whether continuous infusion can optimize pediatric antimicrobial care and healthcare resource utilization. Results will be published in peer-reviewed international journals.
The group in the trial
- Continuous antibiotic infusionTreatment being tested
Treatment: Benzylpenicillin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 8 May 2026